Poor
Partially Aligned
Patient Risk:
Low
Summary
The claims largely do not align with the label's storage guidance. Several claims (notably the 21-day room-temperature window) are not supported by the label. Some storage/travel guidance is correctly reflected, but many assertions are absent or partially inaccurate.
Category Scores
Accurate Statements
After that period, any unused pens must be discarded.
Label requires discard after the applicable storage window (e.g., after first use, up to 14 days at room temperature).
Exposure above 86°F shortens the safe storage window and may reduce the medication’s effectiveness.
Label cautions against exposure to temperatures above 30°C (86°F) as it may affect stability/potency.
If a pen has been left in a hot car or direct sunlight, it should be discarded even if the 21-day mark has not been reached.
Label advises discard if exposed to extreme heat; no extension of the storage window should be assumed.
The clock starts the first time the pen leaves cold storage.
Label indicates storage clock begins when the pen is removed from cold storage.
For trips shorter than 21 days, carry pens in an insulated bag with a cool pack, keeping them between 59°F and 86°F.
Label provides travel/storage guidance to keep pens within 59°F–86°F (15°C–30°C) using insulated bag with cooling.
Unsupported Statements
Mounjaro can stay at room temperature for up to 21 days once it leaves the refrigerator.
Label storage guidance does not support a 21-day room-temperature window; label specifies a shorter duration (e.g., up to 14 days after first use).
This limit applies to both unopened and opened pens as long as they have not been exposed to temperatures above 86°F (30°C).
Label differentiates unopened (refrigerated) versus opened (room temperature) with separate limits; single 86°F limit for both is not supported.
Do not use ice directly against the pens.
Label storage guidance does not explicitly state to avoid direct contact with ice.
Never place them in checked luggage where temperature swings are common.
Label storage section does not reference travel/storage in checked luggage.
Eli Lilly’s primary U.S. patent for tirzepatide, the active ingredient in Mounjaro, is set to expire in 2036.
Patent information is not part of FDA prescribing labeling.
Additional patents on delivery devices and formulations could push broader exclusivity later.
No patent/exclusivity details are included in labeling.
Eli Lilly produces Mounjaro.
Manufacturer information is not part of prescribing label.
No FDA-approved generic or biosimilar versions exist yet.
Label does not discuss generics/biosimilars.
Compounded tirzepatide from certain pharmacies is sometimes used off-label, but these products lack the same manufacturing oversight and stability data as the branded pen.
Label does not address compounding or off-label use.
Contradictions
Low
AI Statement
This limit applies to both unopened and opened pens as long as they have not been exposed to temperatures above 86°F (30°C).
Label Reference
16
Important Omissions
Label states 14 days of room-temperature storage after first use; extracted claims did not include this numeric limit.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Assessment focuses on storage details; no dosing, contraindication, or risk signals identified.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
21-day storage claim not supported by label; incorrect assumption of a single 86°F limit for unopened/opened pens; missing label-specific storage durations (e.g., 14 days after first use) and travel guidance.
Suggested Improvement
Align storage-related claims to the label: specify unopened/refrigerated storage duration, opened pen room-temperature window, and appropriate travel/storage temperatures; remove unsupported 21-day references; include explicit do-not-freeze and do-not-use-in-ice guidance if applicable; ensure consistency with section 16 wording.